Fritextsökning
Artiklar per år
Innehållstyper
-
New antibody aims to slow kidney damage – “It’s kind of cool”
For 25 years, Marie Jeansson has studied the kidney and its blood vessels. She is now working on developing a drug intended to slow down chronic kidney disease.
-
A healthy society requires more than a new pill
Sarah Lidé on how medicines are essential – but a sustainable approach to healthy societies also depends on prevention and behavioural change
-
Asgard teaches tumours to self‑destruct – moving closer to clinical trials
Swedish biotech Asgard Therapeutics not only has an evocative name, but also a remarkably exciting approach to cancer treatment: getting tumour cells to reprogram themselves so that they become visible to the body’s immune system.
-
FDA leaders seek to scrap two-study requirement
A single pivotal study may be sufficient to secure approval for a new medicine in the United States. That is the message delivered by FDA Commissioner Marty Makary and the agency’s medical and scientific chief, Vinay Prasad, in an article in the New England Journal of Medicine.
-
Björn Arvidsson: ”As uncertainty grows, clarity becomes a strength”
Sweden has all the prerequisites to be a strong life science nation. But in a time of geopolitical tension, shorter value chains and growing demands for resilience, it is no longer enough to be “good at many things”, Björn Arvidsson writes in a column.
-
“BioArctic is Leqembi, but also much more”
What once began as a small Swedish biotech company has grown into a fully fledged pharmaceutical company with global reach. At the helm is Gunilla Osswald, who joined early on and is now leading BioArctic into its next era.
-
Genovis ramps up in ADC technology: “An area where we’re seeing very strong interest”
With new products and an expanded licensing agreement in hand Genovis now has a partly new focus for its operations: ADCs – or antibody‑drug conjugates.
-
Study: Autism as common in girls as in boys
Autism may be just as common in girls as in boys, but girls are diagnosed significantly later and less often during childhood, according to a large Swedish registry study.
-
Gene therapies on clinical hold after tumour found in five‑year‑old
The development of a brain tumour in a study participant has led the FDA to temporarily halt two ongoing gene therapy programs. The affected company, Regenxbio, immediately lost nearly one‑fifth of its market value.
-
Swedish drug development projects in Phase III – studies to keep an eye on
Developing new medicines is, as we know, a lengthy and uncertain process, and only a fraction of all projects ever reach late clinical phase. But it does happen – and here we highlight a number of promising Swedish drug candidates currently in Phase III that are worth watching more closely.
-
“The US matters most – even in times of turbulence”
Tariffs, geopolitical uncertainty and rapidly changing trade conditions mean that Swedish life science companies need more routes into global markets – and faster support to understand what actually applies. That is the view of Johan Chun, newly appointed Head of Industry at Business Sweden.
-
Positive outcome in phase III for Sanofi’s eczema treatment
The antibody amlitelimab shows positive Phase III data as a treatment for atopic dermatitis. France‑based Sanofi now plans to submit global regulatory applications before the end of the year.
-
Novo Nordisk Foundation commits billions to Danish life science incubator
The Novo Nordisk Foundation grants up to DKK 5.5 billion to life science and deep‑tech incubator Bioinnovation Institute (BII) in Copenhagen.
-
Investor Network Backs Early-Stage Nordic Innovation
Life Science Invest is expanding into the Nordic region and has secured SEK 31 million to invest in early-stage research companies. The capital will be invested in around ten life science companies over the coming year.
-
Fourteen US-based top researchers recruited to Sweden
Sweden has set its sights on America’s top scholars – and it seems to work. By the end of 2025, fourteen leading U.S.-based researchers had already been won over to Swedish universities.
-
Obesity dominates as future blockbusters are identified
Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.
BREAKING